MDXH Key Statistics, Chart & Performance
The current stock price of MDXH is 3.7 USD. In the past month the price increased by 9.38%. In the past year, price increased by 93.72%.
MDXH Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to MDXH. When comparing the yearly performance of all stocks, MDXH is one of the better performing stocks in the market, outperforming 88.77% of all stocks.
MDXH Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to MDXH. Both the profitability and financial health of MDXH have multiple concerns.
MDXH Financial Highlights
Over the last trailing twelve months MDXH reported a non-GAAP Earnings per Share(EPS) of -0.64. The EPS increased by 57.89% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -33.59% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
MDXH Forecast & Estimates
12 analysts have analysed MDXH and the average price target is 7.18 USD. This implies a price increase of 94.08% is expected in the next year compared to the current price of 3.7.
For the next year, analysts expect an EPS growth of 53.68% and a revenue growth 22.89% for MDXH
MDXH Ownership
About MDXH
Company Profile
MDxHealth SA is a commercial-stage precision diagnostics company, which engages in the development and commercialization of molecular diagnostic products for personalized cancer treatment. The company is headquartered in Herstal, Liege and currently employs 312 full-time employees. The company went IPO on 2006-06-26. The Company’s tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, as well as prediction of response to a specific therapy. Its tests include ConfirmMDx for Prostate Cancer, SelectMDx for Prostate Cancer, PredictMDx for Glioblastoma and AssureMDx for Bladder Cancer. The firm's corporate operations are based in Herstal, Belgium, as well as Irvine, the United States, and its laboratory operations are based in Nijmegen, the Netherlands, as well as Irvine, the United States.
Company Info
MDXHEALTH
CAP Business Center, Rue d'Abhooz 31
Herstal LIEGE BE
Employees: 312
Phone: 3243642070
MDXHEALTH / MDXH FAQ
Can you describe the business of MDXHEALTH?
MDxHealth SA is a commercial-stage precision diagnostics company, which engages in the development and commercialization of molecular diagnostic products for personalized cancer treatment. The company is headquartered in Herstal, Liege and currently employs 312 full-time employees. The company went IPO on 2006-06-26. The Company’s tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, as well as prediction of response to a specific therapy. Its tests include ConfirmMDx for Prostate Cancer, SelectMDx for Prostate Cancer, PredictMDx for Glioblastoma and AssureMDx for Bladder Cancer. The firm's corporate operations are based in Herstal, Belgium, as well as Irvine, the United States, and its laboratory operations are based in Nijmegen, the Netherlands, as well as Irvine, the United States.
What is the stock price of MDXHEALTH today?
The current stock price of MDXH is 3.7 USD. The price decreased by -0.27% in the last trading session.
Does MDXHEALTH pay dividends?
MDXH does not pay a dividend.
What is the ChartMill rating of MDXHEALTH stock?
MDXH has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the number of employees for MDXHEALTH?
MDXHEALTH (MDXH) currently has 312 employees.
What is the ownership structure of MDXHEALTH (MDXH)?
You can find the ownership structure of MDXHEALTH (MDXH) on the Ownership tab.